Literature DB >> 10742693

Turning a corner on HIV neutralization?

J H Nunberg1, K E Follis, M Trahey, R A LaCasse.   

Abstract

HIV vaccine development has been hampered by the inability of conventional immunogens to elicit antibodies capable of neutralizing primary isolates of the virus. Recent studies using 'fusion-competent' immunogens that capture transitional intermediate structures of the functioning envelope protein suggest that this goal may now be achievable.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10742693     DOI： 10.1016/s1286-4579(00)00267-7

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  6 in total

1.  Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein.

Authors:  D Lavillette; B Boson; S J Russell; F L Cosset
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.

Authors:  Christine Hager-Braun; Elisabeth O Hochleitner; Miroslaw K Gorny; Susan Zolla-Pazner; Rachelle J Bienstock; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2010-03-31       Impact factor: 3.109

3.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.

Authors:  James M Binley; Charmagne S Cayanan; Cheryl Wiley; Norbert Schülke; William C Olson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

Authors:  J York; K E Follis; M Trahey; P N Nyambi; S Zolla-Pazner; J H Nunberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.